Azithromycin & Omeprazole Interaction

Azithromycin (a macrolide antibiotic) and omeprazole (a proton pump inhibitor) are commonly co-administered, as patients requiring antibiotics may also be taking PPIs for acid reflux, GERD, or gastroprotection. The interaction between these two medications is considered minor and clinically insignificant in most circumstances.

The primary theoretical concern is that omeprazole raises gastric pH, which could affect the dissolution and absorption of azithromycin. Azithromycin is acid-labile in its uncoated form, but modern oral formulations are designed to be stable across a range of gastric pH values. Clinical data suggest that omeprazole does not significantly alter azithromycin bioavailability.

Additionally, both drugs have been reported to have effects on the QT interval — azithromycin can prolong QT, and omeprazole has a very rare association with hypomagnesemia leading to secondary QT prolongation. However, the combined risk is very low at standard doses.

Azithromycin is absorbed primarily in the small intestine, and its oral bioavailability is approximately 37%. Modern tablet and suspension formulations are formulated to resist gastric acid degradation, so the increase in gastric pH from omeprazole has minimal impact on azithromycin stability or absorption. Omeprazole irreversibly inhibits the H+/K+ ATPase proton pump in gastric parietal cells, raising gastric pH to 4-7. Azithromycin is not significantly metabolized by cytochrome P450 enzymes and does not meaningfully inhibit CYP isoforms, so there is no significant pharmacokinetic interaction via hepatic metabolism. The QT-related concern is pharmacodynamic: azithromycin can block hERG potassium channels leading to QT prolongation, while chronic PPI use can rarely cause hypomagnesemia, which independently predisposes to QT prolongation.

The clinical significance is low. Pharmacokinetic studies have not demonstrated a clinically meaningful reduction in azithromycin exposure when co-administered with PPIs. A large observational study published in the New England Journal of Medicine identified azithromycin as having a small but statistically significant association with cardiovascular death (related to QT prolongation), but this risk was not specifically increased by PPI co-administration. The hypomagnesemia risk from PPIs is primarily associated with long-term use (over 1 year) and is not relevant for the short-duration overlap that occurs during a typical azithromycin course (3-5 days).

No dose adjustments are needed for either medication. Azithromycin can be taken regardless of meals (tablet form) and regardless of PPI use. Complete the full course of azithromycin as prescribed. Continue omeprazole at its usual dose and schedule. If a patient has been on long-term PPI therapy, ensure magnesium levels have been checked at some point, as this is standard PPI monitoring regardless of azithromycin use.

No specific monitoring is required for this drug combination beyond standard care. For patients on long-term PPI therapy, periodic serum magnesium checks are recommended by the FDA regardless of antibiotic use. If a patient has known risk factors for QT prolongation (congenital long QT syndrome, hypokalemia, hypomagnesemia, concurrent QT-prolonging drugs, heart failure), an ECG may be prudent before starting azithromycin. Monitor for resolution of the infection being treated.